Avient Corporation vs Novavax Inc — how do they compare? Avient Corporation trades at $44.88 (market cap $4.17B), while Novavax Inc trades at $7.9 (market cap $1.31B). The key difference: Avient Corporation is far larger — about 3.2× Novavax Inc's market cap, and Avient Corporation pays a 2.42% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| AVNT | NVAX | |
|---|---|---|
Market Cap | $4.17B | $1.31B |
Sector | Technology | Health |
52-Week High | $45.69 | $11.19 |
52-Week Low | $27.48 | $6.22 |
Enterprise Value | $5.62B | $889.30M |
Dividend Yield | 2.42% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Trailing returns across standard periods
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →